A new experimental cancer vaccine targeting mutations in the KRAS gene has demonstrated encouraging results in preventing the recurrence of pancreatic and colorectal cancers, according to a clinical trial led by the UCLA Health Jonsson Comprehensive Cancer Center. The vaccine, known as ELI-002 2P, was tested on 25 patients who had undergone surgery for these cancers.
Those patients had all experienced